Online citations, reference lists, and bibliographies.
← Back to Search

Solid Lipid Nanoparticles (SLN

E. Souto, J. Fangueiro, R. Mueller
Published 2013 · Materials Science

Cite This
Download PDF
Analyze on Scholarcy
Share
Solid lipid nanoparticles (SLN™) are a new generation of drug delivery systems being exploited for several drugs since the nineties. These particles can be composed of different types of solid lipids, such as glycerides, waxes, and fatty acids, and stabilized by a wide range of surfactants. In the present chapter, the chemical structure, production methodology, and physicochemical characterization are systematically discussed. Parameters such as particle size, distribution, polymorphic behaviour, and crystallization are required to characterize SLN and may predict their in vitro stability and in vivo profile, therefore structural parameters can influence the biopharmaceutical properties. The use of SLN for drug delivery is also dependent on their toxicological profile in vitro. Nanotoxicology is also discussed addressing the key points that may limit the clinical use of SLN.
This paper references
10.1016/S0378-5173(99)00426-3
Comparison of wax and glyceride solid lipid nanoparticles (SLN).
V. Jenning (2000)
10.1016/j.ijpharm.2008.07.028
Cyclosporine A loaded SLNs: evaluation of cellular uptake and corneal cytotoxicity.
E. Gokce (2008)
10.1016/S0076-6879(09)64006-4
Chapter 6 - Solid lipid nanoparticle formulations pharmacokinetic and biopharmaceutical aspects in drug delivery.
E. Souto (2009)
10.1016/S0927-7765(02)00053-X
Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules
M. Garcia-Fuentes (2003)
10.1155/2012/750891
Current State-of-Art and New Trends on Lipid Nanoparticles (SLN and NLC) for Oral Drug Delivery
P. Severino (2012)
10.1166/JBN.2011.1332
AmbiOnp: solid lipid nanoparticles of amphotericin B for oral administration.
Pratikkumar A. Patel (2011)
10.3109/02652040903031279
Solid lipid nanoparticles produced through a coacervation method
L. Battaglia (2010)
10.1016/j.ijpharm.2011.12.037
Loading hydrophilic drug in solid lipid media as nanoparticles: statistical modeling of entrapment efficiency and particle size.
M. Ghadiri (2012)
10.1016/J.ADDR.2007.04.011
Solid lipid nanoparticles for targeted brain drug delivery.
P. Blasi (2007)
10.1016/S0939-6411(00)00087-4
Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art.
R. Mueller (2000)
10.1016/j.ijpharm.2011.08.042
Cationic solid lipid nanoparticles (cSLN): structure, stability and DNA binding capacity correlation studies.
S. Doktorovová (2011)
10.1016/j.nano.2011.12.007
Preclinical evaluation of a pulmonary delivered paclitaxel-loaded lipid nanocarrier antitumor effect.
M. Videira (2012)
10.1080/02652040500435295
Investigation of the factors influencing the incorporation of clotrimazole in SLN and NLC prepared by hot high-pressure homogenization
E. Souto (2006)
Solid Lipid Nanoparticles (SLN’S) – Trends and Implications in Drug Targeting
V. Sinha (2010)
10.1016/j.ijpharm.2008.02.011
Inhaled nanoparticles--a current review.
W. Yang (2008)
10.1016/S0939-6411(01)00157-6
Bioavailability of diazepam from aqueous-organic solution, submicron emulsion and solid lipid nanoparticles after rectal administration in rabbits.
M. Sznitowska (2001)
10.1021/AC010380M
Fourier transform infrared imaging: theory and practice.
R. Bhargava (2001)
10.1016/S0378-5173(02)00081-9
Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization.
F. Hu (2002)
10.1016/S1369-7021(04)00628-5
Development of nanotechnologies
A. P. Dowling (2004)
10.1016/j.jconrel.2012.01.017
Oral drug delivery research in Europe.
R. Mrsny (2012)
10.1002/JPS.10413
Influence of emulsifiers on the crystallization of solid lipid nanoparticles.
H. Bunjes (2003)
10.1016/J.EJPB.2004.02.015
Evaluation of the physical stability of SLN and NLC before and after incorporation into hydrogel formulations.
E. Souto (2004)
10.2136/SSSAJ2004.7360
Critical Evaluation of the Use of Laser Diffraction for Particle-Size Distribution Analysis
G. Eshel (2004)
10.1016/j.nano.2009.02.003
Nanomedicines for ocular NSAIDs: safety on drug delivery.
J. Araújo (2009)
10.1016/j.ijbiomac.2008.06.006
The use of solid lipid nanoparticles to target a lipophilic molecule to the liver after intravenous administration to mice.
W. Lu (2008)
10.1016/j.ijpharm.2011.02.001
Cryogenic transmission electron microscopy (cryo-TEM) for studying the morphology of colloidal drug delivery systems.
J. Kuntsche (2011)
10.1016/S1773-2247(11)50008-5
Solid lipid nanoparticles for drug delivery
M. Harms (2011)
Long-circulating and target-specific nanoparticles: theory to practice.
S. Moghimi (2001)
10.1016/j.ijpharm.2009.10.020
Solid lipid nanoparticles as potential tools for gene therapy: in vivo protein expression after intravenous administration.
A. del Pozo-Rodríguez (2010)
10.1016/S0168-3659(97)00046-1
Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential
K. Westesen (1997)
Differential scanning calorimetry techniques: applications in biology and nanoscience.
P. Gill (2010)
10.1016/j.colsurfb.2012.01.018
Solid lipid nanoparticles: continuous and potential large-scale nanoprecipitation production in static mixers.
Yuancai Dong (2012)
10.1016/j.nano.2011.04.006
Pathogen-mimetic stealth nanocarriers for drug delivery: a future possibility.
Miguel A. S. Cavadas (2011)
10.1016/S0378-5173(99)00216-1
Pseudolatex preparation using a novel emulsion-diffusion process involving direct displacement of partially water-miscible solvents by distillation.
D. Quintanar-Guerrero (1999)
10.1016/J.JCONREL.2004.04.001
Glucocorticoid entrapment into lipid carriers--characterisation by parelectric spectroscopy and influence on dermal uptake.
R. Sivaramakrishnan (2004)
10.1016/S0006-3495(78)85397-1
Dynamic light scattering from solutions of microtubules.
J. Gethner (1978)
10.1016/S0939-6411(03)00020-1
Scanning electron microscopy and atomic force microscopy imaging of solid lipid nanoparticles derived from amphiphilic cyclodextrins.
Alix Dubes (2003)
10.1007/s10973-011-1871-4
Loading of praziquantel in the crystal lattice of solid lipid nanoparticles
A. L. R. D. Souza (2011)
10.1016/J.ADDR.2003.12.002
Solid lipid nanoparticles for parenteral drug delivery.
S. Wissing (2004)
10.1111/J.1467-2494.2004.00252_4.X
Comparative study between the viscoelastic behaviors of different lipid nanoparticle formulations.
E. Souto (2004)
10.1016/j.colsurfb.2011.07.036
Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables.
S. Das (2011)
10.3109/10611860903338462
Preparation, characterization, and evaluation of gatifloxacin loaded solid lipid nanoparticles as colloidal ocular drug delivery system
M. A. Kalam (2010)
10.1016/S1369-7021(09)70201-9
AFM and combined optical techniques
N. Geisse (2009)
10.1016/j.colsurfb.2009.01.001
Effect of electromagnetic field and surface modification on the electrical behavior of novel solid lipid nanoparticles covered with l-arginine.
Y. Kuo (2009)
10.1016/j.nano.2010.06.003
Preparation and characterization of ketoprofen-loaded solid lipid nanoparticles made from beeswax and carnauba wax.
Soheila Kheradmandnia (2010)
10.1016/J.EJPB.2007.02.006
Re-dispersible cationic solid lipid nanoparticles (SLNs) freeze-dried without cryoprotectors: characterization and ability to bind the pEGFP-plasmid.
E. Vighi (2007)
10.1016/J.COLSURFA.2007.07.035
Effect of beeswax modification on the lipid matrix and solid lipid nanoparticle crystallinity
A. Attama (2008)
10.1016/0378-5173(93)90177-H
Investigations on the physical state of lipid nanoparticles by synchrotron radiation X-ray diffraction
K. Westesen (1993)
10.1016/0009-3084(82)90053-6
The use of differential scanning calorimetry and differential thermal analysis in studies of model and biological membranes.
R. N. Mcelhaney (1982)
10.2174/187221111797200597
New methods for lipid nanoparticles preparation.
F. Corrias (2011)
10.1016/j.ejpb.2010.05.003
Non-destructive methods of characterization of risperidone solid lipid nanoparticles.
Z. Rahman (2010)
10.1002/anie.201001493
Imaging of self-assembled structures: interpretation of TEM and cryo-TEM images.
H. Friedrich (2010)
10.1016/j.ijpharm.2010.01.030
pDNA condensation capacity and in vitro gene delivery properties of cationic solid lipid nanoparticles.
E. Vighi (2010)
10.1517/17425247.2012.673278
Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery
L. Battaglia (2012)
10.1080/03639040600640006
The Metabolism of Fatty Alcohols in Lipid Nanoparticles by Alcohol Dehydrogenase
X. Dong (2006)
10.1038/sj.bjp.0701396
Anti‐inflammatory activity of cationic lipids
M. Filion (1997)
10.1016/S0168-3659(01)00506-5
Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA.
C. Olbrich (2001)
10.1016/j.addr.2011.11.013
Microfabrication technologies for oral drug delivery.
Shilpa Sant (2012)
10.1023/A:1016042504830
Atomic Force Microscopy Studies of Solid Lipid Nanoparticles
A. Mühlen (2004)
10.1016/j.ejpb.2010.11.003
Potentials of new nanocarriers for dermal and transdermal drug delivery.
R. Neubert (2011)
10.1016/J.EJPS.2004.10.008
Preparation and characterization of solid lipid nanoparticles (SLN) made of cacao butter and curdlan.
Byung-Do Kim (2005)
10.1201/9781315274287
Principles of colloid and surface chemistry
P. C. Hiemenz (1977)
10.1016/0378-5173(92)90303-J
Preparation of submicron drug particles in lecithin-stabilized o/w emulsions I. Model studies of the precipitation of cholesteryl acetate
B. Sjoestroem (1992)
10.1080/02652040600612439
Polymorphic behaviour of Compritol®888 ATO as bulk lipid and as SLN and NLC
E. Souto (2006)
10.1016/J.EJPB.2007.07.006
Cyclosporine-loaded solid lipid nanoparticles (SLN): drug-lipid physicochemical interactions and characterization of drug incorporation.
R. Mueller (2008)
10.1016/S0142-9612(03)00331-4
Physico-chemical stability of colloidal lipid particles.
B. Heurtault (2003)
10.1201/B14204-9
Thermal Methods of Analysis
J. Mccauley (1995)
10.1016/j.colsurfb.2012.01.001
Design and evaluation of polymer coated carvedilol loaded solid lipid nanoparticles to improve the oral bioavailability: a novel strategy to avoid intraduodenal administration.
Vinay Kumar Venishetty (2012)
10.1201/9780203505281.CH3
Characterization of Solid Lipid Nano-and Microparticles
H. Bunjes (2004)
10.3109/02652040902846883
Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery
E. Başaran (2010)
10.1016/j.ijpharm.2008.04.023
Solid lipid nanoparticles for retinal gene therapy: transfection and intracellular trafficking in RPE cells.
A. Del Pozo-Rodríguez (2008)
10.1016/j.colsurfb.2009.09.033
Formulating fluticasone propionate in novel PEG-containing nanostructured lipid carriers (PEG-NLC).
S. Doktorovová (2010)
10.1016/S0378-5173(00)00361-6
Studies on the cyclosporin A loaded stearic acid nanoparticles.
Q. Zhang (2000)
10.1016/J.IJPHARM.2006.01.042
Lecithin-based cationic nanoparticles as a potential DNA delivery system.
Z. Cui (2006)
10.1016/J.EJPB.2005.09.003
Solid lipid nanoparticles can effectively bind DNA, streptavidin and biotinylated ligands.
N. Pedersen (2006)
10.1016/J.ADDR.2007.04.013
Characterization of lipid nanoparticles by differential scanning calorimetry, X-ray and neutron scattering.
H. Bunjes (2007)
10.1016/j.ejmech.2012.01.001
Preparation and optimization of PIT solid lipid nanoparticles via statistical factorial design.
C. Carbone (2012)
10.1016/j.colsurfb.2009.11.006
Electrophoresis of human brain microvascular endothelial cells with uptake of cationic solid lipid nanoparticles: effect of surfactant composition.
Y. Kuo (2010)
10.1016/j.ejps.2011.12.015
Multivariate design for the evaluation of lipid and surfactant composition effect for optimisation of lipid nanoparticles.
S. Martins (2012)
10.1016/j.ejpb.2011.03.022
The physical state of lipid nanoparticles influences their effect on in vitro cell viability.
Silvia Petersen (2011)
10.1016/J.TUBE.2004.11.003
Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis.
R. Pandey (2005)
10.1016/j.ijpharm.2008.01.008
Solid lipid nanoparticles for pulmonary delivery of insulin.
J. Liu (2008)
10.1016/j.ijpharm.2011.12.011
Physicochemical characterization of curcuminoid-loaded solid lipid nanoparticles.
A. Noack (2012)
10.1111/j.1467-2494.2006.00320.x
Sunblocking efficiency of various TiO2‐loaded solid lipid nanoparticle formulations 1
E. Cengiz (2006)
10.1080/1061186021000054933
Lymphatic Uptake of Pulmonary Delivered Radiolabelled Solid Lipid Nanoparticles
M. Videira (2002)
10.1016/j.ijpharm.2011.07.035
Lipid nanoparticles for brain targeting I. Formulation optimization.
P. Blasi (2011)
10.1016/j.ejps.2010.05.007
Arthemeter-loaded lipid nanoparticles produced by modified thin-film hydration: Pharmacokinetics, toxicological and in vivo anti-malarial activity.
N. P. Aditya (2010)
10.1002/9780470027318.A6801
X-Ray Techniques: Overview
R. Jenkins (2006)
10.1016/J.PARTIC.2007.12.002
Progress in nanoparticles characterization: Sizing and zeta potential measurement
R. Xu (2008)
10.1016/j.ejps.2011.12.016
Modified Rose Bengal assay for surface hydrophobicity evaluation of cationic solid lipid nanoparticles (cSLN).
S. Doktorovová (2012)
10.1016/S0939-6411(02)00123-6
AFM imaging of calixarene based solid lipid nanoparticles in gel matrices.
P. Shahgaldian (2003)
10.1016/J.JCONREL.2004.02.029
Transfection with different colloidal systems: comparison of solid lipid nanoparticles and liposomes.
K. Tabatt (2004)
10.1016/j.nano.2009.04.008
Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery.
B. Mishra (2010)
10.3109/10837450.2011.591804
A novel lipid nanocarrier for insulin delivery: production, characterization and toxicity testing
J. Fangueiro (2013)
10.1016/J.ADDR.2007.04.007
Solid lipid nanoparticles as a drug delivery system for peptides and proteins.
A. Almeida (2007)
10.1016/j.ejpb.2010.02.014
A toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug delivery system for the lung.
M. Nassimi (2010)
10.1002/0471670561
Surfactants and Interfacial Phenomena
M. Rosen (1978)
10.3109/02652048.2010.517854
Chitosan-associated SLN: in vitro and ex vivo characterization of cyclosporine A loaded ophthalmic systems
G. Sandri (2010)
10.1002/CHIN.200244254
Polymorphism and Phase Transitions of Fatty Acids and Acylglycerols
F. Kaneko (2002)
10.1080/10717540590968855
Solid Lipid Nanoparticles Containing Tamoxifen Characterization and In Vitro Antitumoral Activity
G. Fontana (2005)
10.1016/S0378-5173(02)00080-7
Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin.
R. Cavalli (2002)
10.1016/S1369-7021(04)00233-0
Scaffolds for tissue fabrication
P. Ma (2004)
10.1016/J.CARBPOL.2010.12.042
Effect of chitosan coating in overcoming the phagocytosis of insulin loaded solid lipid nanoparticles by mononuclear phagocyte system
B. Sarmento (2011)
The use of SLN and NLC as topical particulate carriers for imidazole antifungal agents.
E. Souto (2006)
10.1016/j.addr.2011.12.001
Fast-Scan DSC and its role in pharmaceutical physical form characterisation and selection.
J. L. Ford (2012)
10.1016/j.ejps.2010.10.002
Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting.
M. R. Aji Alex (2011)
10.1016/S0168-3659(96)01559-3
Interaction of a Lecithin Microemulsion Gel with Human Stratum Corneum and its Effect on Transdermal Transport
F. Dreher (1997)
10.1016/j.colsurfb.2011.03.029
Polymorphism, crystallinity and hydrophilic-lipophilic balance of stearic acid and stearic acid-capric/caprylic triglyceride matrices for production of stable nanoparticles.
P. Severino (2011)
10.1016/S0378-5173(97)04885-0
Peptide-loaded solid lipid nanoparticles (SLN): Influence of production parameters
A. J. Almeida (1997)
10.1016/S0032-5910(00)00242-4
New developments in particle characterization by laser diffraction: size and shape
Zhenhua Ma (2000)
10.1016/j.colsurfb.2011.07.060
Solid lipid nanoparticles comprising internal Compritol 888 ATO, tripalmitin and cacao butter for encapsulating and releasing stavudine, delavirdine and saquinavir.
Y. Kuo (2011)
Pharmaceutical Particulate Matter: Analysis and Control
T. Barber (1993)
10.1080/02713680903017500
Sustained Release and Permeation of Timolol from Surface-Modified Solid Lipid Nanoparticles through Bioengineered Human Cornea
A. Attama (2009)
10.1016/J.JCONREL.2005.06.006
Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration.
K. Manjunath (2005)
10.1016/J.EJPB.2005.03.006
Characterisation of surface-modified solid lipid nanoparticles (SLN): influence of lecithin and nonionic emulsifier.
M. Schubert (2005)
10.1016/S1773-2247(11)50005-X
Lipid-based colloidal systems (nanoparticles, microemulsions) for drug delivery to the skin: materials and end-product formulations
E. Souto (2011)
10.1007/s10973-011-1645-z
Thermodynamic behavior of lipid nanoparticles upon delivery of Vitamin E derivatives into the skin: in vitro studies
J. Fangueiro (2011)
10.1023/A:1016121319668
A Novel Phase Inversion-Based Process for the Preparation of Lipid Nanocarriers
B. Heurtault (2004)
Dynamic Light Scattering: With Applications to Chemistry, Biology, and Physics
B. J. Berne (1976)
10.1016/j.addr.2011.05.004
Adaptive micro and nanoparticles: temporal control over carrier properties to facilitate drug delivery.
Jin-Wook Yoo (2011)
10.1016/J.EJPS.2005.10.004
Structural investigations on lipid nanoparticles containing high amounts of lecithin.
M. Schubert (2006)
10.1016/J.CEJ.2008.07.024
Preparation of solid lipid nanoparticles in co-flowing microchannels
Songhong Zhang (2008)
10.1016/J.JCONREL.2003.06.003
The use of FT-IR imaging as an analytical tool for the characterization of drug delivery systems.
Carrie A Coutts-Lendon (2003)
10.1007/978-3-642-00477-3_4
Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes.
E. Souto (2010)
10.1016/S0378-5173(02)00035-2
Lipase degradation of Dynasan 114 and 116 solid lipid nanoparticles (SLN)--effect of surfactants, storage time and crystallinity.
C. Olbrich (2002)
10.1016/J.POWTEC.2010.02.035
Effect of lipid nanoparticles containing fatty alcohols having different chain length on the ex vivo skin permeability of Econazole nitrate
V. Sanna (2010)
10.1016/J.COCIS.2011.06.007
Structural properties of solid lipid based colloidal drug delivery systems
H. Bunjes (2011)
10.1016/J.EJPB.2004.03.028
Physicochemical characterization of colloidal drug delivery systems such as reverse micelles, vesicles, liquid crystals and nanoparticles for topical administration.
C. Müller-Goymann (2004)
10.1016/j.ijpharm.2008.08.050
Entrapment and release of saquinavir using novel cationic solid lipid nanoparticles.
Y. Kuo (2009)



This paper is referenced by
Long-term Retinol Decomposition Profile and Emulsion Chassis & Package Impact to Destabilization
H. Kim (2017)
10.1038/s41598-020-65953-7
Use of biogenic silver nanoparticles in enhancing shelf life of Morus alba L. at post harvest stage
D. Das (2020)
10.1136/bjophthalmol-2015-308250
Developing transcutaneous nanoenabled anaesthetics for eyelid surgery
A. Lalatsa (2016)
SELF ASSEMBLED CYCLODEXTRIN NANOPARTICLES AS DRUG CARRIER
P. Patil (2014)
10.1016/j.ijpharm.2016.02.019
Lipid-based nanoformulations for peptide delivery.
N. Matougui (2016)
10.3109/02652048.2011.590612
Solid lipid nanoparticles and nanosuspension formulation of Saquinavir: preparation, characterization, pharmacokinetics and biodistribution studies
Shamsunder S Dodiya (2011)
10.2217/NNM-2016-0265
Lipid-based nanocarriers for the oral administration of biopharmaceutics.
T. Karamanidou (2016)
Evaluation of the safety and drug delivery efficacy of carbon dots in in vitro and in vivo models
Jiahui Fan (2018)
10.1016/j.ejpb.2014.12.023
Current nanotechnology approaches for the treatment and management of diabetic retinopathy.
J. Fangueiro (2015)
10.3109/21691401.2016.1160407
Development and characterization of embelin-loaded nanolipid carriers for brain targeting
Nancy Sharma (2017)
10.17265/2328-2150/2016.07.004
Multi-methodological Approach to Evaluate Performances of Mucoadhesive Oral Gel Based on Nanoparticles
Capra (2016)
10.1016/j.jddst.2019.101350
A concise review on cancer treatment methods and delivery systems
Elham Bidram (2019)
10.1016/B978-0-323-42868-2.00001-2
Advances in nanobiomaterials for topical administrations: new galenic and cosmetic formulations
P. Severino (2016)
10.1016/B978-0-12-804305-9.00009-9
Encapsulation of nutraceuticals in novel delivery systems
J. Fangueiro (2016)
10.1016/j.colsurfb.2014.09.042
Physicochemical characterization of epigallocatechin gallate lipid nanoparticles (EGCG-LNs) for ocular instillation.
J. Fangueiro (2014)
Cationic Lipid Nanomedicines for the treatment of Diabetic retinopathy
J. Fangueiro (2015)
10.3389/fbioe.2016.00071
The Quest for Anti-inflammatory and Anti-infective Biomaterials in Clinical Translation
M. Griffith (2016)
10.1016/j.ijpharm.2016.02.039
Biopharmaceutical evaluation of epigallocatechin gallate-loaded cationic lipid nanoparticles (EGCG-LNs): In vivo, in vitro and ex vivo studies.
Joana F. Fangueiro (2016)
10.1007/s11095-015-1677-3
Dual Drug Delivery Using Lactic Acid Conjugated SLN for Effective Management of Neurocysticercosis
R. Devi (2015)
10.1007/s40005-018-00418-8
Potential of nanoparticulate carriers for improved drug delivery via skin
Alam Zeb (2018)
REVIEW ON NANOPARTICLES USED IN COSMETICS AND DERMAL PRODUCTS
S. Patwekar (2014)
10.1007/s11051-015-3306-9
Detection and analysis of human serum albumin nanoparticles within phagocytic cells at the resolution of individual live cell or single 3D multicellular spheroid
E. Afrimzon (2015)
Semantic Scholar Logo Some data provided by SemanticScholar